Clinical Trials Results
Results for the search you initiated will be displayed below.
Trial Name
Brief Summary
The study is being conducted to determine whether neoadjuvant endocrine therapy with
fulvestrant or the combination of anastrozole and fulvestrant, is better than anastrozole
when given before surgery to shrink the cancer and stop it from growing. Anastrozole inhibits
tumor growth by reducing the levels of estrogen and has been approved by the Food and Drug
Administration (FDA) of the United States for use after surgery for postmenopausal women with
estrogen receptor positive breast cancer. It is also considered a standard of care to give
anastrozole for a few months before surgery to shrink the tumor. Fulvestrant inhibits tumor
cell growth by reducing the levels of estrogen receptor in the tumor cell. It is not approved
by the FDA for use in women with early stage breast cancer before or after surgery, but is
approved by the FDA for patients with advanced (Stage 4) estrogen receptor positive breast
cancer that has spread to other parts of the body.
This randomized phase III trial studies axillary lymph node dissection to see how well it
works compared to axillary radiation therapy in treating patients with node-positive breast
cancer treated with neoadjuvant chemotherapy followed by surgery. Lymph node dissection may
remove cancer cells that have spread to nearby lymph nodes in patients with breast cancer.
Radiation therapy uses high-energy x-rays to kill tumor cells. This study will evaluate
whether radiation therapy is as effective as lymph node dissection.
This randomized phase III trial studies whether weight loss in overweight and obese women may
prevent breast cancer from coming back (recurrence). Previous studies have found that women
who are overweight or obese when their breast cancer is found (diagnosed) have a greater risk
of their breast cancer recurring, as compared to women who were thinner when their cancer was
diagnosed. This study aims to test whether overweight or obese women who take part in a
weight loss program after being diagnosed with breast cancer have a lower rate of cancer
recurrence as compared to women who do not take part in the weight loss program. This study
will help to show whether weight loss programs should be a part of breast cancer treatment.
This randomized phase III trial studies how well aspirin works in preventing the cancer from
coming back (recurrence) in patients with human epidermal growth factor receptor 2 (HER2)
breast cancer after chemotherapy, surgery, and/or radiation therapy. Aspirin is a drug that
reduces pain, fever, inflammation, and blood clotting. It is also being studied in cancer
prevention. Giving aspirin may reduce the rate of cancer recurrence in patients with breast
cancer.
This phase II trial studies the side effects and how well palbociclib and letrozole or
fulvestrant works in treating patients aged 70 years and older with estrogen receptor
positive, HER2 negative breast cancer that has spread to other places in the body.
Palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth. Drugs used in chemotherapy, such as letrozole or fulvestrant, work in different
ways to stop the growth of tumor cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Giving palbociclib and letrozole or fulvestrant
may work better in treating patients with breast cancer. The trial will explore factors other
than chronologic age that can affect toxicity rates as identified using a cancer-specific
geriatric assessment.
This phase III trial evaluates mammographic breast density in participants with hormone
receptor-negative breast cancer enrolled on study A011502. High breast density has been shown
to be a strong risk factor for developing breast cancer and decreasing breast density may
decrease the risk for breast cancer. Participants treated with aspirin may show reduced
breast density on a mammogram.
This randomized phase III trial studies standard or comprehensive radiation therapy in
treating patients with early-stage breast cancer who have undergone surgery. Radiation
therapy uses high-energy x rays to kill tumor cells. It is not yet known whether
comprehensive radiation therapy is more effective than standard radiation therapy in treating
patients with breast cancer
This randomized phase II/III trial studies how well standard of care therapy with
stereotactic radiosurgery and/or surgery works and compares it to standard of care therapy
alone in treating patients with breast cancer that has spread to one or two locations in the
body (limited metastatic) that are previously untreated. Standard of care therapy comprising
chemotherapy, hormonal therapy, biological therapy, and others may help stop the spread of
tumor cells. Radiation therapy and/or surgery is usually only given with standard of care
therapy to relieve pain; however, in patients with limited metastatic breast cancer,
stereotactic radiosurgery, also known as stereotactic body radiation therapy, may be able to
send x-rays directly to the tumor and cause less damage to normal tissue and surgery may be
able to effectively remove the metastatic tumor cells. It is not yet known whether standard
of care therapy is more effective with stereotactic radiosurgery and/or surgery in treating
limited metastatic breast cancer.
This randomized phase III trial studies how well doxorubicin hydrochloride and
cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients
with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin
hydrochloride, cyclophosphamide, paclitaxel, and carboplatin, work in different ways to stop
the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. It is not yet known whether doxorubicin hydrochloride and
cyclophosphamide is more effective when followed by paclitaxel alone or paclitaxel and
carboplatin in treating triple-negative breast cancer.
This randomized phase III trial studies how well cisplatin or carboplatin (platinum based
chemotherapy) works compared to capecitabine in treating patients with remaining (residual)
basal-like triple-negative breast cancer following chemotherapy after surgery (neoadjuvant).
Drugs used in chemotherapy, such as cisplatin, carboplatin and capecitabine, work in
different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. It is not yet known whether cisplatin
or carboplatin is more effective than capecitabine in treating patients with residual triple
negative basal-like breast cancer.
This phase II trial studies F-18 16 alpha-fluoroestradiol (FES) positron emission tomography
(PET)/computed tomography (CT) in predicting response to endocrine therapy in patients with
newly diagnosed breast cancer that has spread to other parts of the body. FES is a
radioactive form of the hormone estrogen and may "light up" where cancer is in the body.
Diagnostic procedures using FES, such as FES PET/CT, may help measure the FES and help
doctors predict how well the cancer will respond to treatment.
This phase II MATCH trial studies how well treatment that is directed by genetic testing
works in patients with solid tumors or lymphomas that have progressed following at least one
line of standard treatment or for which no agreed upon treatment approach exists. Genetic
tests look at the unique genetic material (genes) of patients' tumor cells. Patients with
genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more
from treatment which targets their tumor's particular genetic abnormality. Identifying these
genetic abnormalities first may help doctors plan better treatment for patients with solid
tumors, lymphomas, or multiple myeloma.
This phase II trial studies how well docetaxel or paclitaxel work in reducing
chemotherapy-induced peripheral neuropathy in African American patients with stages I-III
breast cancer. Drugs used in chemotherapy, such as docetaxel and paclitaxel, work in
different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. It is not yet known whether giving
docetaxel or paclitaxel may work better than other methods in reducing chemotherapy-induced
peripheral neuropathy in patients with breast cancer.
The purpose of this study is to compare the effects on low risk breast cancer receiving usual
care that includes regional radiation therapy, with receiving no regional radiation therapy.
Researchers want to see if not giving this type of radiation treatment works as well at
preventing breast cancer from coming back.
This randomized phase III trial studies how well paclitaxel, trastuzumab, and pertuzumab with
or without atezolizumab works in treating patients with breast cancer that has spread to
other parts of the body (metastatic). Drugs used in chemotherapy, such as paclitaxel, work in
different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Trastuzumab is a form of "targeted
therapy" because it works by attaching itself to specific molecules (receptors) on the
surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2
receptors, the signals that tell the cells to grow are blocked and the cancer cell may be
marked for destruction by the body's immune system. Monoclonal antibodies, such as
pertuzumab, may interfere with the ability of cancer cells to grow and spread. Immunotherapy
with monoclonal antibodies, such as atezolizumab, may induce changes in body's immune system
and may interfere with the ability of tumor cells to grow and spread. It is not yet known
whether giving paclitaxel, trastuzumab, and pertuzumab with or without atezolizumab may kill
more tumor cells.
This phase II trial studies how well biopsy of breast after chemotherapy works in predicting
pathologic response in patients with stage II-IIIA breast cancer undergoing breast conserving
surgery. Tumor tissue collected from biopsy before surgery may help to check if chemotherapy
destroyed the breast cancer cells and may be compared to the tumor removed during surgery to
check if they are the same.
This phase II randomized trial studies how well bupropion hydrochloride works in improving
sexual desire in women with breast or gynecological cancer. Bupropion hydrochloride may work
by boosting sexual desire, energy, or motivation without causing intolerable or undesirable
side effects.
This randomized phase III trial studies how well pembrolizumab works in treating patients
with triple-negative breast cancer. Immunotherapy with monoclonal antibodies, such as
pembrolizumab, may help the body's immune system attack the cancer, and may interfere with
the ability of tumor cells to grow and spread.
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in
patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has
spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat
heart failure and high blood pressure, and it may prevent the heart from side effects of
chemotherapy.
This randomized research trial studies how well serum tumor marker directed disease
monitoring works in monitoring patients with hormone receptor positive Her2 negative breast
cancer that has spread to other places in the body. Using markers to prompt when scans should
be ordered may be as good as the usual approach to monitoring disease.
This phase II trial studies how well radiation therapy with or without olaparib works in
treating patients with inflammatory breast cancer. Radiation therapy uses high energy x-rays
to kill tumor cells and shrink tumors. Olaparib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. It is not yet known whether radiation
therapy with or without olaparib may work better in treating patients with inflammatory
breast cancer.
This study is to compare the safety and effects of donepezil (Aricept) for patients reporting
cognitive or memory issues after receiving chemotherapy for breast cancer. Patients will
receive either donepezil or placebo for 24 weeks. The primary objective is to see if memory
improves with the use of donepezil during the study.
This study is being done to see if patients receiving chemotherapy for breast cancer affects
the heart, the ability to exercise and fatigue when compared to patients who do not have
cancer.
Clinical Trial Categories:
- Bone Cancer
- Brain Cancer
- Breast Cancer
- Cancer Control
- Companion Studies
- Gastrointestinal Cancer
- Genitourinary Cancer
- Gynecology (GYN) Cancer
- Head and Neck Cancer
- Leukemia
- Lung Cancer
- Lymphoma (Hodgkin's Disease, Non-Hodgkin's Lymphoma)
- Melanoma
- Multiple Myeloma
- Myelodysplastic Syndrome (MDS)
- Other Cancer Protocols
- Pancreas Cancer
- Sarcoma
- Skin Cancer
- Symptom Management